Investigational Drug Information for Resiquimod
✉ Email this page to a colleague
What is the drug development status for Resiquimod?
Resiquimod is an investigational drug.
There have been 17 clinical trials for Resiquimod.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2005.
The most common disease conditions in clinical trials are Warts, Melanoma, and Influenza, Human. The leading clinical trial sponsors are Graceway Pharmaceuticals, LLC, Spirig Pharma Ltd., and National Cancer Institute (NCI).
Summary for Resiquimod
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 5,788 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 859 |
| Clinical Trial Progress | Phase 2 (2005-03-01) |
| Vendors | 65 |
Recent Clinical Trials for Resiquimod
| Title | Sponsor | Phase |
|---|---|---|
| A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors | Ascendis Pharma Oncology Division A/S | Phase 1/Phase 2 |
| A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients | Case Comprehensive Cancer Center | Phase 1/Phase 2 |
| Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) Agonists | University of British Columbia | Phase 1 |
Clinical Trial Summary for Resiquimod
Top disease conditions for Resiquimod
Top clinical trial sponsors for Resiquimod
US Patents for Resiquimod
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
